At ASCO GU, Karim Fizazi reports PEACE-2 results showing cabazitaxel adds no benefit to ADT and radiotherapy in very high-risk prostate cancer.
Researchers may be closer to developing a vaccine that protects against Epstein-Barr, a common virus linked with infectious mononucleosis, multiple sclerosis, cancers and other serious illnesses, after successfully testing antibodies they developed in mice.
Diabetes is less common among people living at high altitudes, where oxygen levels are low, than at sea level, and researchers who have discovered why that happens say the reason may lead to new treatments.
A two-in-one mRNA vaccine developed by Moderna that targets seasonal influenza and COVID-19 produced robust and durable immune responses without safety concerns in a small mid-stage trial, the company reported.
Patients with one of the deadliest gynecological cancers had dramatically improved survival when an experimental drug was added to treatment with a standard chemotherapy medication in a mid-stage trial in Belarus, researchers say.
Researchers believe they now understand how severe cases of influenza damage the heart, providing an explanation for the annual uptick in heart attacks during flu season.
WORLDSymposium 2026 data highlight AT845, AB‑1009, and ABX1100 as novel approaches for targeting disease pathways in late-onset Pompe disease.
WORLDSymposium 2026: Sustained α-Gal A expression, lyso-Gb3 reduction, and signals of renal and cardiac stability after ST-920 for Fabry disease.
Early cardiac changes, real-world data, and long-term gene therapy results from WORLDSymposium 2026 offer new clinical evidence in Fabry disease.
Newborn-screening data and advances in biochemical screening highlight how early detection and biomarker-guided follow-up shape Pompe care.
Women vaccinated against the human papillomavirus can safely skip many of the cervical cancer screenings that are typically recommended every three to five years, a new study from Norway suggests.
Treatment complexity and emerging options
Targeted therapies may delay ARPI resistance
From diagnostic delays to therapy decisions
Some cancer therapies may be more effective when given earlier in the day, aligning treatment with the body's natural rhythms, a Chinese study found, confirming earlier evidence.
The PRIME trial provides evidence for biparametric MRI as a new standard-of-care alternative to multiparametric MRI in prostate cancer diagnosis.
The immune systems of men appear to be better equipped to shut down pain, which could explain why chronic pain is more common in women, research in mice and humans suggests.
